Differences in non-MHC restricted cytotoxic activities of human peripheral blood lymphocytes after transfusion with allogeneic leukocytes or platelets possessing class I and/or class II MHC molecules.
MHC-unrestricted cytotoxic activity of peripheral blood lymphocytes (PBL) from 4-6 healthy donors was investigated before and after transfusion with allogeneic leukocytes or platelets. Natural killer and lectin-dependent cellular cytotoxicity (LDCC) of PBL was tested against K562 and Raji target cells in a 4-h and 16-h 51Cr-release assay, respectively. After allotransfusion with leukocytes, we found increased cytotoxic activity of each donor's PBL against all the three targets on day 3 or 7. The highest non-specific cytotoxic activity was detected against the relatively NK resistant Raji target cells. The increase of cytotoxic activity was lowest against the LDCC target (PHA-treated Raji) cells. On the contrary, no changes in cytotoxic activity against any targets were observed after allotransfusion with platelets (possessing class I HLA antigens but no HLA class II molecules). Our results suggest that HLA class II molecules, presumably by inducing immune responses, are essential for activation/generation of non-specific killing of tumor targets after leukocyte transfusion. Thrombocytes, known to be less immunogenic than leukocytes, are not effective in in vivo enhancing of non-specific cytotoxicity. Cellular activation of PBL following leukocyte allotransfusion was confirmed by detection of elevated serum neopterin and beta-2-microglobulin levels on day 3. This was not the case after platelet allotransfusion. In addition, the expression of ICAM-1 antigen (as a molecule involved directly in MHC-unrestricted cytotoxicity) was also found to be increased in two donors' PBL on day 3 after leukocyte transfusion in contrast to transfusion with platelets.
Pócsik
E
E
National Institute of Haematology and Blood Transfusion, Budapest, Hungary.
Mihalik
R
R
Réti
M
M
Gyódi
E
E
Pálóczi
K
K
Mayer
K
K
Kassai
M
M
Herold
M
M
Huber
C
C
Petrányi
G G
GG
D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D001792:Blood Platelets / Q000276:immunology*; D001803:Blood Transfusion; D015815:Cell Adhesion Molecules / Q000032:analysis; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D015200:Fluoroimmunoassay; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D007114:Immunization; D018799:Intercellular Adhesion Molecule-1; D007376:Interleukin-2 / Q000097:blood; D007694:Killer Cells, Natural / Q000276:immunology; D017708:Leukocyte Transfusion; D007962:Leukocytes / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D019798:Neopterin; D017713:Platelet Transfusion; D001613:beta 2-Microglobulin / Q000032:analysis
D015815:Cell Adhesion Molecules; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D001613:beta 2-Microglobulin; D018799:Intercellular Adhesion Molecule-1; D001708:Biopterins; D019798:Neopterin